BioMarin’s PKU Gene Therapy Clinical Hold To Last ‘Several Quarters’
Hemophilia A Candidate Unaffected
BMN 307 for phenylketonuria was put on a clinical hold in September due to liver cancer observed in mice and was expected to lift in Q1 of 2022, but the US FDA has requested additional preclinical studies.
